代表董事會 京玖醫療健康有限公司 公司秘書 林崇謙 2025年8月18日 申請表格 致： 京玖醫療健康有限公司(股份代號： 香港灣仔軒尼斯道8-12號 中港大廈8樓 本人要求索取2025中期報告以及所有未來公司通訊的(i) 英文 / (ii) 中文/ (iii) 英文及中文* 印刷本。 各位非登記股東： 刊發2025 我們現謹通知 閣下，上述公司通訊現已上載於香港聯合交易所有限公司網站 (www.hkexnews.hk)及我們的網站(www.648.com.hk)。倘 閣下擬收取上述公司通訊的印刷本， 請填妥本函背面之申請表格寄回給我們。上述公司通訊的印刷本將在收到要求後免費發送予 閣下。 我們將於公司通訊刊發日期通過電子郵件或郵寄方式向 閣下作為非登記股東發送未 來公司通訊的刊發通知，該通知將同時提供英文和中文版本。為支持環保以電郵方式進行公 司通訊，我們建議 閣下向代 閣下持有股份之銀行、證券行、託管商、代理人或中央結算系 統參與者提供 閣下之電郵地址。 倘 閣下對本通知有任何疑問，請於辦公時間內(星期日及香港公眾假期除外)與我們 的股份過戶登記處卓佳證劵登記有限公司聯絡。 簽署： 日期： 姓名： (英文 ...

各位登記股東： 刊發2025 我們現謹通知 閣下，上述公司通訊現已上載於香港聯合交易所有限公司(「聯交所」)網站 (www.hkexnews.hk)及我們的網站(www.648.com.hk)。 股東如已選擇(或被視為已選擇)以電子方式透過聯交所網站及我們的網站查閱公司通訊(「網上版 本」)，但希望收到上述公司通訊印刷本，請填妥本函背面之更改申請表格之甲部，然後透過郵寄方式將其 寄回給我們。上述公司通訊的印刷本將在收到要求後免費發送予 閣下。 代表董事會 京玖醫療健康有限公司 公司秘書 林崇謙 2025年8月18日 附註： 1. 「公司通訊」乃指我們發出予我們股東參照或採取行動的文件，包括中期報告及年報、會議通告、上市文件、通函或代表委任 表格。 2. 「可供採取行動的公司通訊」乃指尋求我們股東指示的公司通訊，包括股息派付的選擇表格、供股或公開發售之額外申請表格、 供股的暫定配額通知書、公開發售項下保證配額申請表格及有關收購、合併及股份回購的接納表格。 致： 京玖醫療健康有限公司 股份代號： 香港灣仔軒尼斯道8-12號 中港大廈8樓樓 甲部 本人已收到或已選擇(或被視為已選擇)以電子方式收取2025中期報告， ...

Core Viewpoint - Jingjiu Health (00648) reported a mid-year performance for 2025, showing a revenue of HKD 35.771 million, representing a year-on-year increase of 16.5% [1] - The company achieved a profit attributable to shareholders of HKD 3.353 million, a turnaround from a loss of HKD 6.093 million in the same period last year, indicating a successful recovery [1] - Basic earnings per share were reported at HKD 0.01, reflecting the company's improved financial performance [1] Revenue Growth - The revenue growth is primarily attributed to the company's ongoing efforts to expand its product sources and broaden its product portfolio [1]

Core Viewpoint - 京玖康疗 reported a significant improvement in its financial performance for the first half of 2025, achieving a revenue of HKD 35.77 million, which represents a year-on-year increase of 16.5% and a turnaround from a loss to a profit for shareholders [1] Financial Performance - Revenue reached HKD 35.77 million, marking a 16.5% increase compared to the previous year [1] - Shareholders' profit amounted to HKD 3.353 million, a significant recovery from a loss of HKD 6.093 million in the same period last year [1] - Basic earnings per share were reported at HKD 0.01 [1] Growth Drivers - The revenue growth is attributed to the company's ongoing efforts to expand its product sources and broaden its product portfolio [1]

Financial Performance - The company's revenue for the six months ended June 30, 2025, increased by 16.6% to HKD 35.8 million, compared to HKD 30.7 million in 2024[6] - Gross profit for the same period was HKD 11.5 million, with a gross margin of 32.1%, down from 35.1% in 2024[6] - The company achieved a net profit of HKD 3.4 million, recovering from a loss of HKD 6.1 million in 2024, primarily due to a 45.2% reduction in administrative expenses[7] - Revenue for the six months ended June 30, 2025, was HKD 35,771,000, representing a 16.7% increase from HKD 30,704,000 in the same period of 2024[42] - Gross profit for the six months ended June 30, 2025, was HKD 11,483,000, compared to HKD 10,790,000 for the same period in 2024, reflecting a 6.4% increase[42] - The company reported a net profit attributable to owners of HKD 3,353,000 for the six months ended June 30, 2025, compared to a loss of HKD 6,093,000 in the same period of 2024[39] - Operating cash flow generated for the six months ended June 30, 2025, was HKD 1,676,000, a significant improvement from cash used of HKD 11,513,000 in the same period of 2024[40] - The company incurred a loss of HKD 15,131,000 from fair value changes in financial assets for the six months ended June 30, 2024, compared to a loss of HKD 2,815,000 in the same period of 2025[1] - The company recorded a fair value loss of HKD 2,815,000 on listed equity investments during the first half of 2025[55] Cash Flow and Assets - Cash generated from operating activities was HKD 1.7 million, compared to an outflow of HKD 11.5 million in 2024[10] - The company's current assets increased by HKD 7.3 million to HKD 5.5 million, with cash and bank balances at HKD 9.9 million[9] - Cash and cash equivalents increased to HKD 9,923,000 as of June 30, 2025, from HKD 4,051,000 at the end of the same period in 2024[40] - Total assets as of June 30, 2025, were HKD 44,346,000, with total liabilities of HKD 38,537,000, resulting in a net asset value of HKD 5,809,000[45] - Total assets as of June 30, 2025, amounted to HKD 54,667,000, with reported segment assets of HKD 50,372,000[46] - Trade receivables decreased significantly to HKD 9,885,000 as of June 30, 2025, down from HKD 16,739,000 at the end of 2024[56] Liabilities and Equity - The company maintains a total debt level of HKD 31.3 million, similar to HKD 33.1 million as of December 31, 2024[9] - Total liabilities as of June 30, 2025, were HKD 52,211,000, with reported segment liabilities of HKD 31,703,000[46] - The company’s bank loans decreased to HKD 13,293,000 as of June 30, 2025, from HKD 14,436,000 at the end of 2024[58] - The company’s total equity increased to HKD 5,809,000 as of June 30, 2025, compared to HKD 2,456,000 at the beginning of the year[39] Market Outlook and Strategy - The Hong Kong medical equipment market is expected to grow at a rate of 8.3% by 2025 and continue at a CAGR of 7.6% from 2025 to 2030[5] - The company plans to expand its product offerings and strengthen financial resources to participate in suitable public sector project tenders[5] - The company remains optimistic about the Hong Kong medical device market and aims for organic growth through improved business models and increased market penetration[11] Employee and Management - As of June 30, 2025, the company had 20 employees, with employee costs amounting to HKD 1.9 million for the six months ended June 30, 2025, compared to HKD 3.2 million in 2024[19] - The company has implemented a prudent financial management policy, closely monitoring liquidity ratios to meet capital requirements[18] Corporate Governance - The company is committed to maintaining high standards of corporate governance and has complied with the relevant corporate governance code provisions[36] - The audit committee, consisting of three independent non-executive directors, reviewed the interim financial statements, which were not audited but deemed compliant with applicable accounting standards[37] Stock Options and Securities - The total number of stock options available for grant under the plan as of June 30, 2025, is 32,603,682, representing 10% of the issued shares[33] - There were no stock options granted, exercised, expired, or canceled during the six months ended June 30, 2025[27] - The company has a stock option plan that aims to recognize past contributions and incentivize future contributions from eligible participants[25] - The company has not purchased, sold, or redeemed any of its listed securities during the six months ended June 30, 2025[24] - The company has not established a foreign currency hedging policy due to its assets and liabilities being primarily denominated in HKD[17] - The company has not reported any significant foreign exchange risk exposure and will consider hedging measures if necessary[17] Dividends - The company did not declare an interim dividend for the reporting period, consistent with 2024[52] Other Information - No significant capital raising activities or major investments were completed during the six months ended June 30, 2025[12][13] - There were no significant events affecting the company's operations or financial performance after June 30, 2025[60]

Financial Performance - The company reported revenue of HKD 30,704,000 for the six months ended June 30, 2025, compared to HKD 30,704,000 for the same period in 2024, indicating no growth year-over-year[4] - Gross profit for the period was HKD 10,790,000, with a gross margin of approximately 35.1%[4] - The company incurred a loss attributable to owners of HKD 6,093,000, compared to a loss of HKD 4,793,000 in the previous year, reflecting a deterioration in performance[4] - The company reported a revenue growth of 16.6% to HKD 35.8 million for the six months ended June 30, 2025, compared to HKD 30.7 million in 2024[28] - The gross profit for the same period was HKD 11.5 million, with a gross margin of 32.1%, down from 35.1% in 2024[28] - The company achieved a net profit of HKD 3.4 million for the six months ended June 30, 2025, recovering from a loss of HKD 6.1 million in 2024[29] - The company’s basic and diluted loss per share for the period was HKD 1.0 cents, compared to a loss of HKD 1.9 cents per share in the previous year[4] Assets and Liabilities - The total assets as of June 30, 2025, were HKD 44,346,000, while total liabilities were HKD 38,537,000, resulting in a net asset value of HKD 2,456,000[5] - The company’s total liabilities increased from HKD 52,211,000 as of December 31, 2024, to HKD 38,537,000 as of June 30, 2025, indicating a reduction in overall debt[10] - As of June 30, 2025, the group's net current assets increased by HKD 7.3 million to HKD 5.5 million, including cash and bank balances of HKD 9.9 million (December 31, 2024: HKD 8.8 million)[31] - The group's current ratio improved to 1.15 as of June 30, 2025 (December 31, 2024: 1.05)[31] - The total borrowings remained relatively stable at HKD 31.3 million as of June 30, 2025 (December 31, 2024: HKD 33.1 million)[31] Income and Expenses - The company reported other income of HKD 8,471,000, which included rental income of HKD 309,000 and other income of HKD 8,162,000[12] - The financing costs for the period amounted to HKD 486,000, which included interest expenses on bank loans and lease liabilities[13] - Administrative expenses decreased by 45.2% to HKD 4.6 million, down from HKD 8.4 million in 2024, due to effective cost control measures[29] - The fair value loss on listed equity investments was HKD 2.8 million for the six months ended June 30, 2025, compared to HKD 15.1 million in 2024[30] Business Operations - The company’s medical and health business generated external sales of HKD 35,771,000, with a segment profit of HKD 8,662,000[9] - The company has one reportable segment, which is the distribution of medical and health equipment and products, with no new segments introduced during the reporting period[8] - The company has not acquired any property, plant, and equipment during the six months ended June 30, 2025[18] - The Hong Kong medical equipment market is expected to grow at a rate of 8.3% in 2025 and continue at a compound annual growth rate of 7.6% from 2025 to 2030[27] - The company plans to expand its product sources and portfolio while maintaining its market position and providing high-quality services[27] - The group remains optimistic about the Hong Kong medical device market and aims for organic growth through improved business models and increased market penetration[33] Employee and Management - As of June 30, 2025, the group had 20 employees, with employee costs amounting to HKD 1.9 million for the six months ended June 30, 2025 (2024: HKD 3.2 million)[41] - The board of directors is actively seeking suitable candidates to fill the vacant positions of chairman and CEO[58] Corporate Governance - The company is committed to maintaining high standards of corporate governance and has complied with the corporate governance code during the reporting period[58] - The audit committee, composed of three independent non-executive directors, has reviewed the interim financial statements and found them compliant with applicable accounting standards[59] - The company has adopted the standards set out in Appendix C3 of the listing rules to regulate securities trading by directors[57] Stock Options - The stock option plan is effective for 10 years starting from June 30, 2025, subject to early termination provisions[53] - The total number of stock options available for grant as of June 30, 2025, is 32,603,682, representing 10% of the issued shares as of the report date[55] - The board of directors must not grant stock options that would result in any participant holding more than 1% of the total issued shares within any 12-month period without shareholder approval[54] - There are no other share-linked agreements in place during the reporting period or as of June 30, 2025, apart from the stock option plan[56] Financial Management - The group maintained a cautious financial management policy, closely monitoring liquidity ratios to meet capital requirements[40] - The group has not completed any equity fundraising activities during the six months ended June 30, 2025[34] - There were no significant investments or acquisitions during the six months ended June 30, 2025[35] - The group has no significant assets pledged as collateral as of June 30, 2025[37]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就本公告全部或任何部份內容而產生或因倚賴該 等內容而引致之任何損失承擔任何責任。 本公司股份將繼續暫停買賣，以待達成復牌條件。本公司股東及潛在投資者於買賣本公司股份 時務請審慎行事。 代表董事會 京玖醫療健康有限公司 公司秘書 林崇謙 香港，2025 年 8 月 6 日 於本公告日期，本公司董事會包括林品卓先生為執行董事，及樂可慰先生、唐萃環女士及姚 俊榮先生為獨立非執行董事。 董事會召開日期 京玖醫療健康有限公司(「本公司」)董事會宣佈將於 2025 年 8 月 18 日(星期一)舉行董事會會 議，以批准刊發本公司及其附屬公司截至 2025 年 6 月 30 日之未經審核中期業績。 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 截至月份: | 2025年7月31日 | 狀態: 新提交 | | --- | --- | --- | | 致：香港交易及結算所有限公司 | | | | 公司名稱: | 京玖醫療健康有限公司 | | | 呈交日期: | 2025年8月6日 | | | I. 法定/註冊股本變動 不適用 | | | FF301 第 1 頁 共 10 頁 v 1.1.1 FF301 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00648 | 說明 | 京玖康療 | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 326,036,828 | | 0 | | 326,036,828 | | 增加 / 減少 (-) | | | 0 ...

Core Viewpoint - The company, Jingjiu Kangliao (00648.HK), has received a notification from the Stock Exchange regarding the temporary suspension of delisting procedures, contingent on further developments with the Securities and Futures Commission [1] Group 1: Company Operations - The company primarily engages in the distribution of medical and health equipment and products in Hong Kong, and its operations are continuing as normal in all significant aspects [1] - The board of directors will continue to monitor the impact of the suspension on the company's operations and financial performance, taking appropriate measures as necessary [1] Group 2: Stock Trading Status - The company's shares will remain suspended from trading until the conditions for resumption are met [1] - Shareholders and potential investors are advised to exercise caution when trading the company's shares [1]

復牌之最新資料 本公告乃由本公司根據上市規則第 13.24A 條作出，並提述本公司日期為 2025 年4月30日的公告。 本公告所用之詞彙與該公告所界定者具有相同涵義。 復牌進度更新 聯交所於 2020 年 4 月 21 日知會本公司將暫不行使上市規則第 6.01A(2)(b)(i)條權利將本公司除牌， 惟視乎本公司向證監會呈請之進一步發展情況，可能在其認為適當的情況，於較後階段行使上市 規則第 6.01A 條權利。本公司會繼續解決證監會及聯交所的關注。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性或 完整性亦不發表任何聲明，並明確表示概不就本公告全部或任何部份內容而產生或因倚賴該等內 容而引致之任何損失承擔任何責任。 本公司股份將繼續暫停買賣，以待達成復牌條件。本公司股東及潛在投資者於買賣本公司股份時 務請審慎行事。 代表董事會 京玖醫療健康有限公司 公司秘書 林崇謙 香港，2025 年 7 月 31 日 於本公告日期，本公司董事會包括林品卓先生為執行董事，及樂可慰先生、唐萃環女士及姚俊榮 先生為獨立非執行董事。 本集團主要於香港從事分銷醫療及健康設備及產品之醫療及健康 ...